S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Molecular Templates Stock Forecast, Price & News

-0.08 (-1.86%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
163,323 shs
Average Volume
330,970 shs
Market Capitalization
$237.61 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter.

Molecular Templates logo

About Molecular Templates

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2000 and is headquartered in Austin, TX.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$18.84 million
Book Value
$1.28 per share


Net Income
$-104.92 million
Net Margins
Pretax Margin




Free Float
Market Cap
$237.61 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.57 out of 5 stars

Medical Sector

83rd out of 1,391 stocks

Pharmaceutical Preparations Industry

33rd out of 669 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -

Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

Is Molecular Templates a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Molecular Templates stock.
View analyst ratings for Molecular Templates
or view top-rated stocks.

How has Molecular Templates' stock price been impacted by COVID-19 (Coronavirus)?

Molecular Templates' stock was trading at $13.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MTEM shares have decreased by 68.1% and is now trading at $4.22.
View which stocks have been most impacted by COVID-19

Are investors shorting Molecular Templates?

Molecular Templates saw a decrease in short interest in October. As of October 15th, there was short interest totaling 676,900 shares, a decrease of 49.1% from the September 30th total of 1,330,000 shares. Based on an average daily trading volume, of 275,800 shares, the short-interest ratio is presently 2.5 days. Currently, 1.6% of the company's stock are sold short.
View Molecular Templates' Short Interest

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Molecular Templates

How were Molecular Templates' earnings last quarter?

Molecular Templates, Inc. (NASDAQ:MTEM) released its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.16. Molecular Templates had a negative net margin of 417.71% and a negative trailing twelve-month return on equity of 117.50%.
View Molecular Templates' earnings history

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Molecular Templates's stock reverse split before market open on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for MTEM?

3 brokerages have issued 12-month price targets for Molecular Templates' stock. Their forecasts range from $12.00 to $20.00. On average, they expect Molecular Templates' share price to reach $14.50 in the next twelve months. This suggests a possible upside of 243.6% from the stock's current price.
View analysts' price targets for Molecular Templates
or view top-rated stocks among Wall Street analysts.

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the following people:
  • Eric E. Poma, CEO, Director & Chief Scientific Officer
  • Jason S. Kim, President & Chief Operating Officer (LinkedIn Profile)
  • Sean McLennan, CFO, CAO, Senior VP-Finance & Controller
  • Roger J. Waltzman, Chief Medical Officer
  • Megan Filoon, Corporate Counsel

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), TG Therapeutics (TGTX), CEL-SCI (CVM), Pfizer (PFE), Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by many different retail and institutional investors. Top institutional investors include Bellevue Group AG (19.38%), BlackRock Inc. (4.67%), Kingdon Capital Management L.L.C. (1.82%), Geode Capital Management LLC (1.17%), Morgan Stanley (0.72%) and Two Sigma Advisers LP (0.68%). Company insiders that own Molecular Templates stock include Jason S Kim, Kevin M Lalande, Longitude Capital Partners Iii and Target N V Biotech.
View institutional ownership trends for Molecular Templates

Which major investors are selling Molecular Templates stock?

MTEM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Dimensional Fund Advisors LP, Russell Investments Group Ltd., New York State Common Retirement Fund, The Manufacturers Life Insurance Company , Millennium Management LLC, and Panagora Asset Management Inc..
View insider buying and selling activity for Molecular Templates
or view top insider-selling stocks.

Which major investors are buying Molecular Templates stock?

MTEM stock was purchased by a variety of institutional investors in the last quarter, including Bellevue Group AG, Renaissance Technologies LLC, Two Sigma Investments LP, Ensign Peak Advisors Inc, Morgan Stanley, Two Sigma Advisers LP, Cubist Systematic Strategies LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Molecular Templates
or or view top insider-buying stocks.

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $4.22.

How much money does Molecular Templates make?

Molecular Templates has a market capitalization of $237.61 million and generates $18.84 million in revenue each year. The biotechnology company earns $-104.92 million in net income (profit) each year or ($1.90) on an earnings per share basis.

How many employees does Molecular Templates have?

Molecular Templates employs 239 workers across the globe.

When was Molecular Templates founded?

Molecular Templates was founded in 2009.

What is Molecular Templates' official website?

The official website for Molecular Templates is www.mtem.com.

Where are Molecular Templates' headquarters?

Molecular Templates is headquartered at 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at (512) 869-1555, via email at [email protected], or via fax at 650-474-2529.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.